Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Mehta

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Archives of Disease in Childhood|March 15, 2018
Diagnosis of sporadic neurofibromatosis type 2 in the paediatric populationGeetha Anand, Grace Vasallo, Maria Spanou, et al.
Journal of Virology|May 20, 2011
Extensive geographical mixing of 2009 human H1N1 influenza A virus in a single university communityEdward C Holmes, Elodie Ghedin, Rebecca A Halpin, et al.
Chest|July 22, 2020
Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position StatementSamir Gupta, Jane Batt, Jean Bourbeau, et al.
Canadian Respiratory Journal|December 18, 2010
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guidelineSanjay Mehta, Doug Helmersen, Steeve Provencher, et al.
Circulation. Cardiovascular Quality and Outcomes|May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesAdam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
The New England Journal of Medicine|August 30, 2013
Macitentan and morbidity and mortality in pulmonary arterial hypertensionTomás Pulido, Igor Adzerikho, Richard N Channick, et al.
American Heart Journal|June 1, 2002
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionDavid Langleben, Brian W Christman, Robyn J Barst, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Archives of Disease in Childhood|March 15, 2018
Diagnosis of sporadic neurofibromatosis type 2 in the paediatric populationGeetha Anand, Grace Vasallo, Maria Spanou, et al.
Journal of Virology|May 20, 2011
Extensive geographical mixing of 2009 human H1N1 influenza A virus in a single university communityEdward C Holmes, Elodie Ghedin, Rebecca A Halpin, et al.
Chest|July 22, 2020
Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position StatementSamir Gupta, Jane Batt, Jean Bourbeau, et al.
Canadian Respiratory Journal|December 18, 2010
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guidelineSanjay Mehta, Doug Helmersen, Steeve Provencher, et al.
Circulation. Cardiovascular Quality and Outcomes|May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesAdam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
The New England Journal of Medicine|August 30, 2013
Macitentan and morbidity and mortality in pulmonary arterial hypertensionTomás Pulido, Igor Adzerikho, Richard N Channick, et al.
American Heart Journal|June 1, 2002
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionDavid Langleben, Brian W Christman, Robyn J Barst, et al.
Pageof 15